Reference health

CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia

https://doi.org/10.1007/s00428-016-2051-5
CiteStamped reference-health badge
37/37 checkable references clean · checked 2026-07-23

Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.

3 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.

The 37 checked references that resolve
resolves10.1002/hep.24199
Management of Hepatocellular Carcinoma: An Update Δσ
resolves10.1093/annonc/mdv615
Regulation of PD-L1: a novel role of pro-survival signalling in cancer
resolves10.1371/journal.pone.0088543
Dynamic Expression Patterns of Differential Proteins during Early Invasion of Hepatocellular Carcinoma
resolves10.1002/hep.27665
CXCR4 inhibition in tumor microenvironment facilitates anti‐programmed death receptor‐1 immunotherapy in sorafenib‐treated hepatocellular carcinoma in mice
resolves10.1016/j.canlet.2015.06.017
Role of chemokine pathways in hepatobiliary cancer
resolves10.1111/j.1600-065X.2010.00923.x
The PD‐1 pathway in tolerance and autoimmunity
resolves10.1084/jem.192.7.1027
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
resolves10.1038/mt.2015.10
The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer
resolves10.1158/1078-0432.CCR-08-1608
Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
resolves10.1158/1078-0432.CCR-15-2042
The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer
resolves10.1097/PAT.0000000000000320
Prognostic relevance of proliferation markers (Ki-67, PHH3) within the cross-relation of ERG translocation and androgen receptor expression in prostate cancer
resolves10.1002/hep.27246
Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions
resolves10.1038/sj.bjc.6601260
GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON
resolves10.2147/DDDT.S86032
A meta-analysis for C-X-C chemokine receptor type 4 as a prognostic marker and potential drug target in hepatocellular carcinoma
resolves10.1002/j.1460-2075.1992.tb05481.x
Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
resolves10.4143/crt.2016.066
Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
resolves10.1084/jem.20082173
Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1
resolves10.1038/ncomms9494
EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma
resolves10.1038/cmi.2008.46
Roles of Chemokine Receptor 4 (CXCR4) and Chemokine Ligand 12 (CXCL12) in Metastasis of Hepatocellular Carcinoma Cells
resolves10.1002/hep.23046
Adipokines in liver diseases #
resolves10.1053/j.gastro.2014.06.043
Roles for Chemokines in Liver Disease
resolves10.1038/35065016
Involvement of chemokine receptors in breast cancer metastasis
resolves10.1155/2014/808012
Nuclear Pattern of CXCR4 Expression Is Associated with a Better Overall Survival in Patients with Gastric Cancer
resolves10.1084/jem.20131916
PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
resolves10.3390/microarrays3020091
Identification of New Players in Hepatocarcinogenesis: Limits and Opportunities of Using Tissue Microarray (TMA)
resolves10.1002/hep.27332
Hepatic inflammation and fibrosis: Functional links and key pathways
resolves10.1002/ijc.25397
PD‐1 and PD‐L1 upregulation promotes CD8<sup>+</sup> T‐cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients
resolves10.3322/caac.21208
Cancer statistics, 2014
resolves10.2174/1381612821666150105155615
CXCR4 and CXCL12 Expression in Rectal Tumors of Stage IV Patients Before and After Local Radiotherapy and Systemic Neoadjuvant Treatment
resolves10.1146/annurev.pathol.1.110304.100224
TUMOR STROMA AND REGULATION OF CANCER DEVELOPMENT
resolves10.1056/NEJMoa1200690
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
resolves10.1038/nrc.2016.36
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
resolves10.1038/sj.onc.1210751
Epigenetic silencing of CXCL12 increases the metastatic potential of mammary carcinoma cells
resolves10.1038/sj.onc.1209505
Silencing of epithelial CXCL12 expression by DNA hypermethylation promotes colonic carcinoma metastasis
resolves10.1056/NEJMoa1302369
Nivolumab plus Ipilimumab in Advanced Melanoma
resolves10.1002/hep.27320
Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma
resolves10.1371/journal.pone.0023621
Upregulation of Circulating PD-L1/PD-1 Is Associated with Poor Post-Cryoablation Prognosis in Patients with HBV-Related Hepatocellular Carcinoma
The 3 references without a DOI — listed, not checked
no DOI — not checkedGhanem I, Riveiro ME, Paradis V, Faivre S, de Parga PM, Raymond E (2014) Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis. Am J Transl Res 6:340–352
no DOI — not checkedKan G, Dong W (2015) The expression of PD-L1 APE1 and P53 in hepatocellular carcinoma and its relationship to clinical pathology. Eur Rev Med Pharmacol Sci 19:3063–3071
no DOI — not checkedLoncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC, Pastorek J, Ratcliffe PJ, Stratford IJ, West CM (2001) Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61:6394–6399
What this badge says. CiteStamped means the CHECKABLE references of this work were clean at the dated check: each resolved to a known work in a public registry, and none carried a retraction notice at that time. It says nothing about the quality, findings, or importance of the work itself, and nothing about references deposited without a DOI.

checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record

Embed this badge

Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.

<a href="https://citestamp.com/citestamped/10.1007/s00428-016-2051-5"><img src="https://citestamp.com/citestamped/10.1007/s00428-016-2051-5/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[![CiteStamped reference-health badge](https://citestamp.com/citestamped/10.1007/s00428-016-2051-5/badge.svg)](https://citestamp.com/citestamped/10.1007/s00428-016-2051-5)